E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
metastatic or unresectable locally advanced BRAF V600E/K mutation-positive melanoma |
Melanoma localmente avanzado irresecable o metastásico con mutación V600E/K de BRAF |
|
E.1.1.1 | Medical condition in easily understood language |
BRAF V600E/K Mutation-Positive Melanoma |
Melanoma positivo a la mutación V600/K de BRAF |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10040891 |
E.1.2 | Term | Skin melanoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10027156 |
E.1.2 | Term | Skin melanomas (excl ocular) |
E.1.2 | System Organ Class | 100000004858 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10025671 |
E.1.2 | Term | Malignant melanoma stage IV |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10025650 |
E.1.2 | Term | Malignant melanoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025655 |
E.1.2 | Term | Malignant melanoma of skin |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10066600 |
E.1.2 | Term | Melanoma recurrent |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10025670 |
E.1.2 | Term | Malignant melanoma stage III |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10027480 |
E.1.2 | Term | Metastatic malignant melanoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10027150 |
E.1.2 | Term | Melanoma malignant |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10048434 |
E.1.2 | Term | Melanoma malignant aggravated |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10027155 |
E.1.2 | Term | Melanoma skin |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10027152 |
E.1.2 | Term | Melanoma of skin (malignant) |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025658 |
E.1.2 | Term | Malignant melanoma of skin of eyelid, including canthus |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025661 |
E.1.2 | Term | Malignant melanoma of skin of other and unspecified parts of face |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025663 |
E.1.2 | Term | Malignant melanoma of skin of trunk, except scrotum |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025660 |
E.1.2 | Term | Malignant melanoma of skin of lower limb, including hip |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025659 |
E.1.2 | Term | Malignant melanoma of skin of lip |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025656 |
E.1.2 | Term | Malignant melanoma of skin of ear and external auditory canal |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025662 |
E.1.2 | Term | Malignant melanoma of skin of scalp and neck |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025664 |
E.1.2 | Term | Malignant melanoma of skin of upper limb, including shoulder |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025653 |
E.1.2 | Term | Malignant melanoma of other specified sites of skin |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10027153 |
E.1.2 | Term | Melanoma of skin, site unspecified |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025657 |
E.1.2 | Term | Malignant melanoma of skin of ear and external auricular canal |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10027481 |
E.1.2 | Term | Metastatic melanoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10027154 |
E.1.2 | Term | Melanoma of trunk and head |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025666 |
E.1.2 | Term | Malignant melanoma of the anus |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10053571 |
E.1.2 | Term | Melanoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10056768 |
E.1.2 | Term | Malignant melanoma of skin of lower limb, incl hip |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10056767 |
E.1.2 | Term | Malignant melanoma of skin of eyelid, incl canthus |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10056769 |
E.1.2 | Term | Malignant melanoma of skin of upper limb, incl shoulder |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10056792 |
E.1.2 | Term | Malignant melanoma of skin of trunk, excl scrotum |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10077160 |
E.1.2 | Term | Central nervous system melanoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare the efficacy of encorafenib and binimetinib plus pembrolizumab (Triplet Arm) versus nivolumab and ipilimumab (Control Arm) with respect to ORR. |
Comparar la eficacia de encorafenib y binimetinib más pembrolizumab (grupo del triplete) frente a nivolumab e ipilimumab (grupo de control) con respecto a la TRG |
|
E.2.2 | Secondary objectives of the trial |
- To compare the efficacy of the Triplet Arm versus the Control Arm with respect to PFS. - To compare the efficacy of the Triplet Arm versus the Control Arm with respect to OS. |
- Comparar la eficacia del grupo del triplete frente al grupo de control con respecto a la SSP. - Comparar la eficacia del grupo del triplete frente al grupo de control con respecto a la SG |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Participants must meet the following key inclusion criteria to be eligible for enrollment into the study: - Male or female participants ≥18 years of age at the time of informed consent. - Histologically confirmed unresectable (Stage IIIB, IIIC, or IIID) or metastatic (Stage IV) cutaneous melanoma, according to the AJCC 8th edition. - Documented evidence of a BRAF V600E or V600K mutation. - Submission of adequate tumor tissue for central laboratory testing of BRAF V600E/K mutation and biomarkers is required for all participants during the screening period and prior to randomization. - Must have received only 1 prior line of systemic therapy for melanoma (either adjuvant therapy or first-line anti-PD-1 monotherapy (ie, nivolumab or pembrolizumab). - Must have anti-PD-1 resistant disease (primary or secondary) with confirmed disease progression per RECIST v1.1 either during or after receipt of an approved anti-PD-1 monotherapy (ie, nivolumab or pembrolizumab) for melanoma, defined according to the SITC Immunotherapy Resistance Taskforce (Kluger et al, 2020). - Have at least 1 measurable lesion per RECIST v1.1. - ECOG PS of 0-1, and adequate organ and cardiac function, including LVEF ≥50% by cardiac imaging. |
Los participantes deberán cumplir los siguientes criterios de inclusión clave para ser aptos para su inclusión en el estudio: • Participantes de ambos sexos #18 años en el momento del consentimiento informado. • Melanoma cutáneo irresecable (estadio IIIB, IIIC o IIID) o metastásico (estadio IV) confirmado histológicamente, de acuerdo con la 8.a edición del JCC. • Evidencia documentada de una mutación V600E o V600K de BRAF. • Es necesario enviar tejido tumoral adecuado para los análisis de la mutación V600E/K de BRAF y biomarcadores del laboratorio central de todos los participantes durante la fase de selección y antes de la aleatorización. • Deben haber recibido solo 1 línea previa de tratamiento sistémico para el melanoma (ya sea un tratamiento adyuvante o una monoterapia de primera línea con anti-PD-1, es decir, nivolumab o pembrolizumab). • Deben tener enfermedad resistente a anti-PD-1 (primaria o secundaria) con progresión confirmada de la enfermedad según los RECIST v1.1 durante o después de recibir una monoterapia aprobada con anti-PD-1 (es decir, nivolumab o pembrolizumab) para el melanoma, definida según el Grupo de Trabajo de la Resistencia a la Inmunoterapia (Immunotherapy Resistance Taskforce) de la SITC (Kluger et al., 2020). • Tener al menos 1 lesión medible según los RECIST v1.1. • EF del ECOG de 0-1 y función orgánica y cardíaca adecuadas, incluida una FEVI #50 % según las pruebas de imagen cardíacas. |
|
E.4 | Principal exclusion criteria |
Participants with any of the following key characteristics/conditions will be excluded: - Mucosal or ocular melanoma. - Diagnosis of immunodeficiency or an active autoimmune disease that required systemic treatment with chronic systemic steroid therapy or any other form of immunosuppressive therapy within the past 2 years. - Clinically significant cardiovascular diseases. - History of thromboembolic or cerebrovascular events ≤12 weeks prior to randomization. - History or current evidence of RVO or current risk factors for RVO. - Concurrent neuromuscular disorder that is associated with the potential of elevated CK. - Active bacterial, fungal, or viral infection requiring systemic therapeutic treatment within 2 weeks prior to randomization. - Current noninfectious pneumonitis/ILD or history of noninfectious pneumonitis/ILD requiring steroids. - Prior or current symptomatic brain metastasis, leptomeningeal disease or other active CNS metastases. - Participants who permanently discontinued prior anti-PD-1 therapy due to toxicity or will be unable to tolerate combination therapy based on investigator judgement are excluded. - Prior treatment with ipilimumab; prior combined immunotherapy blockade with anti- PD-1/L-1; prior treatment with a BRAFi and/or MEKi; or previous administration of an investigational anticancer agent for the adjuvant or first-line treatment of melanoma prior to randomization. - Previous participation in the Pfizer C4221016 STARBOARD Study. |
Se excluirá a los participantes con alguna de las siguientes características/afecciones clave: • Melanoma mucoso u ocular. • Diagnóstico de inmunodeficiencia o enfermedad autoinmunitaria activa que haya requerido tratamiento sistémico con corticoesteroides sistémicos prolongados o cualquier otra forma de tratamiento inmunosupresor en los últimos 2 años. • Enfermedades cardiovasculares clínicamente significativas. • Antecedentes de acontecimientos tromboembólicos o cerebrovasculares #12 semanas antes de la aleatorización. • Antecedentes o evidencia actual de OVR o factores de riesgo actuales de OVR. • Trastorno neuromuscular concomitante relacionado con la posible elevación de la CK. • Infección bacteriana, fúngica o vírica activa que requiera tratamiento terapéutico sistémico en las 2 semanas anteriores a la aleatorización. • Neumonitis/EPI no infecciosa actual o antecedentes de neumonitis/EPI no infecciosa que requieran corticoesteroides. • Metástasis cerebral sintomática previa o actual, enfermedad leptomeníngea u otras metástasis activas del SNC. • Se excluye a los participantes que interrumpieron permanentemente el tratamiento previo con anti-PD-1 debido a toxicidad o que no puedan tolerar el tratamiento combinado a criterio del investigador. • Tratamiento previo con ipilimumab; bloqueo previo de la inmunoterapia combinada con anti-PD-1/L-1; tratamiento previo con un iBRAF o iMEK o administración previa de un fármaco antineoplásico en investigación para el tratamiento adyuvante o de primera línea del melanoma antes de la aleatorización. • Participación previa en el estudio C4221016 STARBOARD de Pfizer. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
ORR, defined as the proportion of participants with a confirmed best overall response of either CR or PR, as determined by investigator assessment per RECIST v1.1 from randomization to the earliest of PD, start of subsequent anticancer therapy, or death due to any cause. |
TRG, definida como la proporción de participantes con una mejor respuesta global confirmada de RC o RP, determinada por el investigador según los RECIST v1.1 desde la aleatorización hasta la PE, el inicio de un tratamiento antineoplásico posterior o la muerte por cualquier causa, lo que ocurra primero. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Throughout the duration of the study; the analysis of ORR and PFS will be both performed at the time on the achievement of the required number of PFS events (88) to run the PFS analysis: assuming non-uniform enrollment over 14 months, 88 PFS events are anticipated to occur approximately 21 months after the first participant is randomized |
A lo largo de la duración del estudio; el análisis de TRG y SSP se realizará en el momento en que se logre la cantidad requerida de eventos de SSP (88) para ejecutar el análisis de SSP: suponiendo una inscripción no uniforme durante 14 meses, se prevé que ocurran 88 eventos de SSP aproximadamente 21 meses después de la asignación aleatoria del primer participante |
|
E.5.2 | Secondary end point(s) |
1. PFS, defined as the interval of time between the date of randomization to the earliest date of disease progression, as determined by investigator assessment per RECIST v1.1, or death due to any cause, whichever occurs first. 2. OS, defined as the time from date of randomization to the date of death due to any cause or the last known alive date. 3. DOR, defined as the time from the date of the first documented response (CR or PR) to the earliest date of disease progression, as determined by investigator assessment per RECIST v1.1, or death due to any cause. 4. DCR, defined as the proportion of participants with a confirmed best overall response of CR, PR or SD, as determined by investigator assessment per RECIST v1.1. 5. TTR, defined as the time from the date of randomization to the date of first documented response (CR or PR), as determined by investigator assessment per RECIST v1.1. 6. PFS2, defined as the time from the date of randomization to the date of discontinuation of next-line treatment after first objective disease progression by investigator assessment per RECIST v1.1, second objective disease progression after initiation of next-line treatment, as determined by investigator assessment, or death due to any cause, whichever occurs first. 7. Incidence and severity of AEs, and changes in clinical laboratory parameters, vital signs, and cardiac assessments. 8. EORTC QLQ-C30: change from baseline in the global health status/QoL score and all other subscales scores. 9. EQ-5D-5L: change from baseline in the index score and VAS. 10. BRAF V600E/K VAF and/or overall mean VAF from ctDNA analysis of plasma samples collected at baseline and on treatment. |
1. SSP, definida como el intervalo de tiempo entre la fecha de aleatorización y la fecha más temprana de progresión de la enfermedad, determinada por el investigador según los RECIST v1.1, o la muerte por cualquier causa, lo que ocurra primero. 2. SG, definida como el tiempo desde la aleatorización hasta la fecha de la muerte por cualquier causa o la última fecha en que se supo que estaban vivos. 3. DdR, definida como el tiempo transcurrido desde la fecha de la primera respuesta documentada (RC o RP) hasta la fecha más temprana de progresión de la enfermedad, determinada por el investigador según los RECIST v1.1, o la muerte por cualquier causa. 4. TCE, definida como la proporción de participantes con una mejor respuesta global confirmada de RC, RP o EE, determinada por el investigador según los RECIST v1.1. 5. TTR, definido como el tiempo transcurrido desde la fecha de la aleatorización hasta la fecha de la primera respuesta documentada (RC o RP), determinado por el investigador según los RECIST v1.1. 6. SSP2, definida como el tiempo transcurrido desde la fecha de aleatorización hasta la fecha de la interrupción del tratamiento de siguiente línea después de la primera progresión objetiva de la enfermedad determinada por el investigador según los RECIST v1.1, la segunda progresión objetiva de la enfermedad después del inicio del tratamiento de siguiente línea, determinada por el investigador o la muerte por cualquier causa, lo que ocurra primero. 7. Incidencia e intensidad de los AA y alteraciones de los parámetros analíticos clínicos, las constantes vitales y las evaluaciones cardíacas. 8. EORTC QLQ-C30: cambio desde el inicio en la puntuación del estado de salud global/CdV y todas las demás puntuaciones de las subescalas. 9. EQ-5D-5L: cambio con respecto al inicio en la puntuación del índice y la EVA. 10. Frecuencia de las variantes alélicas (VAF) de V600E/K de BRAF o VAF media global a partir del análisis de ADNtc de las muestras de plasma recogidas al inicio y durante el tratamiento. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
throughout the study |
a lo largo del estudio |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Tolerability |
tolerabilidad |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 11 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 66 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
Israel |
United States |
Switzerland |
Austria |
Bulgaria |
Czechia |
France |
Germany |
Italy |
Poland |
Slovakia |
Spain |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the study is defined as the point at which all participants have had the opportunity to be followed for at least 32 months after the randomization date of the last participant enrolled and at least 63% of total participants have had an OS event (or were lost to follow-up). |
El fin del estudio se define como el momento en el que todos los participantes han tenido la oportunidad de ser objeto de seguimiento durante un mínimo de 32 meses tras la fecha de aleatorización del último participante inscrito y al menos el 63 % del total de los participantes han experimentado un acontecimiento de SG (o se han perdido para el seguimiento). |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 11 |
E.8.9.2 | In all countries concerned by the trial days | 0 |